Benchmarking recent national practice in rectal cancer treatment with landmark randomized controlled trials. (June 2017)

• Record Type: Journal Article
• Other Names: Borstlap WAA investigator.; Deijen CL investigator.; den Dulk M investigator.; Bonjer HJ investigator.; van de Velde CJ investigator.; Bemelman WA investigator.; Tanis P. J. investigator.; Aalbers A investigator.; Acherman Y investigator.; Algie GD investigator.; von Geusau B Alting investigator.; Amelung F investigator.; Aukema TS investigator.; Bakker IS investigator.; Basha S investigator.; Bastiaansen AJNM investigator.; Belgers E investigator.; Bleeker W investigator.; Blok J investigator.; Bosker RJI investigator.; Bosmans JW investigator.; Boute MC investigator.; Bouvy ND investigator.; Bouwman H investigator.; Brandt‐Kerkhof A investigator.; Brinkman DJ investigator.; Bruin S investigator.; Bruns ERJ investigator.; Burbach JPM investigator.; Burger JWA investigator.; Buskens CJ investigator.; Clermonts S investigator.; Coene PPLO investigator.; Compaan C investigator.; Consten ECJ investigator.; Darbyshire T investigator.; de Mik SML investigator.; de Graaf EJR investigator.; de Groot I investigator.; de vos tot Nederveen Cappel RJL investigator.; de Wilt JHW investigator.; van der Wolde J investigator.; den Boer FC investigator.; Dekker JWT investigator.; Demirkiran A investigator.; Derkx‐Hendriksen M investigator.; Dijkstra FR investigator.; van Duijvendijk P investigator.; Dunker MS investigator.; Eijsbouts QE investigator.; Fabry H investigator.; Ferenschild F investigator.; Foppen JW investigator.; Furnée EJB investigator.; Gerhards MF investigator.; Gerven P investigator.; Gooszen JAH investigator.; Govaert JA investigator.; Van Grevenstein WMU investigator.; Haen R investigator.; Harlaar JJ investigator.; Harst E investigator.; Havenga K investigator.; Heemskerk J investigator.; Heeren JF investigator.; Heijnen B investigator.; Heres P investigator.; Hoff C investigator.; Hogendoorn W investigator.; Hoogland P investigator.; Huijbers A investigator.; Gooszen JAH investigator.; Janssen P investigator.; Jongen AC investigator.; Jonker FH investigator.; Karthaus EG investigator.; Keijzer A investigator.; Ketel JMA investigator.; Klaase J investigator.; Kloppenberg FWH investigator.; Kool ME investigator.; Kortekaas R investigator.; Kruyt PM investigator.; Kuiper JT investigator.; Lamme B investigator.; Lange JF investigator.; Lettinga T investigator.; Lips DJ investigator.; Logeman F investigator.; Holzik MF Lutke investigator.; Madsen E investigator.; Mamound A investigator.; Marres CC investigator.; Masselink I investigator.; Meerdink M investigator.; Menon AG investigator.; Mieog JS investigator.; Mierlo D investigator.; Musters GD investigator.; Neijenhuis PA investigator.; Nonner J investigator.; Oostdijk M investigator.; Oosterling SJ investigator.; Paul PMP investigator.; Peeters KCMJC investigator.; Pereboom ITA investigator.; Polat F investigator.; Poortman P investigator.; Raber M investigator.; Reiber BMM investigator.; Renger RJ investigator.; van Rossem CC investigator.; Rutten HJ investigator.; Rutten A investigator.; Schaapman R investigator.; Scheer M investigator.; Schoonderwoerd L investigator.; Schouten N investigator.; Schreuder AM investigator.; Schreurs WH investigator.; Simkens GA investigator.; Slooter GD investigator.; Sluijmer HCE investigator.; Smakman N investigator.; Smeenk R investigator.; Snijders HS investigator.; Sonneveld DJA investigator.; Spaansen B investigator.; Bilgen EJ Spillenaar investigator.; Steller E investigator.; Steup WH investigator.; Steur C investigator.; Stortelder E investigator.; Straatman J investigator.; Swank HA investigator.; Sietses C investigator.; ten Berge HA investigator.; ten hoeve HG investigator.; ter Riele WW investigator.; Thorensen IM investigator.; Tip‐Pluijm B investigator.; Toorenvliet BR investigator.; Tseng L investigator.; Tuynman JB investigator.; van Bastelaar J investigator.; van beek SC investigator.; van de Ven AWH investigator.; van de Weijer MAJ investigator.; van den Berg C investigator.; van den Bosch I investigator.; van der Bilt JDW investigator.; van der Hagen SJ investigator.; van der hul R investigator.; van der Schelling G investigator.; van der Spek A investigator.; van der Wielen N investigator.; van duyn E investigator.; van Eekelen C investigator.; van Essen JA investigator.; van Gangelt K investigator.; van Geloven AAW investigator.; van kessel C investigator.; van Loon YT investigator.; van Rijswijk A investigator.; van Rooijen SJ investigator.; van Sprundel T investigator.; van Steensel L investigator.; van Tets WF investigator.; van Westreenen HL investigator.; Veltkamp S investigator.; Verhaak T investigator.; Verheijen PM investigator.; Versluis‐Ossenwaarde L investigator.; Vijfhuize S investigator.; Vles WJ investigator.; Voeten S investigator.; Vogelaar FJ investigator.; Vrijland WW investigator.; Westerduin E investigator.; Westerterp ME investigator.; Wetzel M. investigator.; Wevers K investigator.; Wiering B investigator.; Witjes AC investigator.; Wouters MW investigator.; Yauw STK investigator.; Zeestraten EC investigator.; Zimmerman DD investigator.; Zwieten T investigator.;
• Is Part Of: Colorectal disease. Volume 19:Number 6(2017)
• Page Start: O219
• Page End: O231
• Publication Date: 2017-06
• Subjects: Rectal cancer -- snapshot study -- oncologic outcomes; Colon (Anatomy) -- Diseases -- Periodicals; Rectum -- Diseases -- Periodicals; 616.34
• DOI: 10.1111/codi.13644
• Languages: English
• ISSNs: 1462-8910

Abstract

Abstract: Aim: A Snapshot study design eliminates changes in treatment and outcome over time. This population based Snapshot study aimed to determine current practice and outcome of rectal cancer treatment with published landmark randomized controlled trials as a benchmark. Method: In this collaborative research project, the dataset of the Dutch Surgical Colorectal Audit was extended with additional treatment and long‐term outcome data. All registered patients who underwent resection for rectal cancer in 2011 were eligible. Baseline characteristics and outcome were evaluated against the results of the Dutch TME trial and the COLOR II trial from which the original datasets were obtained. Results: A total of 71 hospitals participated, and data were completed for 2102 out of the potential 2633 patients (79.8%). Median follow‐up was 41 (interquartile range 25–47) months. Overall circumferential resection margin (CRM) involvement was 9.3% in the Snapshot cohort and 18.5% in the Dutch TME trial. CRM positivity after laparoscopic resection was 7.8% in the Snapshot and 9.5% in the COLOR II trial. Three‐year overall local recurrence rate in the Snapshot was 5.9%, with a disease‐free survival of 67.1% and overall survival of 79.5%. Benchmarking with the randomized controlled trials revealed an overall favourable long‐term outcome of the Snapshot cohort. Conclusion: This study showed that current rectal cancer care in a large unselected Dutch population is of high quality, with less positive CRM since the TME trial and oncologically safe implementation of minimally invasive surgery after the COLOR II trial.